Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial

Umberto Restelli1 Center for Health Economics, Social and Health Care Management, LIUC – Università Cattaneo, Castellanza, Italy;2 School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South AfricaCorrespondence[email protected]

Massimiliano Fabbiani3 Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart

Simona Di Giambenedetto3 Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart

Carmela Nappi4 Health Economics, Bristol Myers Squibb S.r.l., Rome, Italy

Davide Croce1 Center for Health Economics, Social and Health Care Management, LIUC – Università Cattaneo, Castellanza, Italy;2 School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date